Ally Bridge Group’s Praxis Precision Medicines PRAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.6M Buy
32,810
+12,928
+65% +$4M 8.54% 1
2025
Q4
$5.86M Buy
+19,882
New +$3.7M 6.1% 9
2025
Q3
Sell
-80,880
Closed -$3.92M 33
2025
Q2
$3.4M Sell
80,880
-14,702
-15% -$560K 2.83% 18
2025
Q1
$3.62M Buy
95,582
+50,600
+112% +$3.16M 3.26% 10
2024
Q4
$3.46M Sell
44,982
-28,203
-39% -$2.04M 2.97% 14
2024
Q3
$4.21M Sell
73,185
-80,194
-52% -$4.33M 2.25% 27
2024
Q2
$6.34M Sell
153,379
-6,107
-4% -$289K 3.78% 13
2024
Q1
$9.73M Buy
159,486
+89,062
+126% +$4M 5.41% 7
2023
Q4
$1.57M Sell
70,424
-1
-0% -$18 0.93% 18
2023
Q3
$1.81M Sell
70,425
-142,908
-67% -$2.7M 2.12% 15
2023
Q2
$3.68M Buy
+213,333
New +$3.27M 4.46% 11
2023
Q1
Sell
-42,039
Closed -$1.5M 32
2022
Q4
$1.5M Buy
+42,039
New +$1.31M 1.46% 24

Other funds holding PRAX

Ally Bridge Group's PRAX Position: Q1 2026 in Review

Ally Bridge Group increased its Praxis Precision Medicines (PRAX) stake by 65% in Q1 2026, buying an estimated $4M and bringing the position to 32,810 shares worth $10.6M. The position accounts for 8.54% of the portfolio, ranked #1.

Ally Bridge Group first reported a position in PRAX in Q4 2022 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Ally Bridge Group held 32,810 shares of Praxis Precision Medicines worth $10.6M as of Q1 2026.
  • Ally Bridge Group bought 12,928 Praxis Precision Medicines shares in Q1 2026, an estimated $4M.
  • Praxis Precision Medicines made up 8.54% of Ally Bridge Group's portfolio in Q1 2026, its #1 holding.
  • Ally Bridge Group first reported a position in Praxis Precision Medicines in Q4 2022 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.